Therapeutic T cell engineering
Top Cited Papers
- 25 May 2017
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature
- Vol. 545 (7655), 423-431
- https://doi.org/10.1038/nature22395
Abstract
Genetically engineered T cells are powerful new medicines, offering hope for curative responses in patients with cancer. Chimaeric antigen receptors (CARs) are a class of synthetic receptors that reprogram lymphocyte specificity and function. CARs targeting CD19 have demonstrated remarkable potency in B cell malignancies. Engineered T cells are applicable in principle to many cancers, pending further progress to identify suitable target antigens, overcome immunosuppressive tumour microenvironments, reduce toxicities, and prevent antigen escape. Advances in the selection of optimal T cells, genetic engineering, and cell manufacturing are poised to broaden T-cell-based therapies and foster new applications in infectious diseases and autoimmunity.Keywords
This publication has 170 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- CD19 CAR-Targeted T Cells Induce Long-Term Remission and B Cell Aplasia in an Immunocompetent Mouse Model of B Cell Acute Lymphoblastic LeukemiaPLOS ONE, 2013
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced LeukemiaScience Translational Medicine, 2011
- T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient ColitisMolecular Therapy, 2011
- Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safetyLeukemia, 2010
- Increased Intensity Lymphodepletion Enhances Tumor Treatment Efficacy of Adoptively Transferred Tumor-specific T CellsJournal of Immunotherapy, 2010
- Adoptively transferred effector cells derived from naïve rather than central memory CD8 + T cells mediate superior antitumor immunityProceedings of the National Academy of Sciences of the United States of America, 2009
- Rational development of high-affinity T-cell receptor-like antibodiesProceedings of the National Academy of Sciences of the United States of America, 2009
- Tumor immunotherapy across MHC barriers using allogeneic T-cell precursorsNature Biotechnology, 2008
- A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating LymphocytesScience, 1986